Wilbanks Smith & Thomas Asset Management’s Alnylam Pharmaceuticals ALNY Stock Holding History

Wilbanks Smith & Thomas Asset Management’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-1,000	Closed	-$200K	–	515
2023 Q1	$200K	Hold	1,000	–	–	0.01%	490
2022 Q4	$238K	Hold	1,000	–	–	0.01%	433
2022 Q3	$200K	Buy	+1,000	New	+$191K	0.01%	449

Other funds holding ALNY

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Wilbanks Smith & Thomas Asset Management's ALNY Position: Q2 2023 in Review

Wilbanks Smith & Thomas Asset Management sold out of Alnylam Pharmaceuticals (ALNY) in Q2 2023, closing a stake of 1,000 shares — an estimated $200K sold.

Wilbanks Smith & Thomas Asset Management first reported a position in ALNY in Q3 2022 and held it in 3 quarters. The position peaked at $238K in Q4 2022. 476 funds tracked by Wall St. Rank hold ALNY as of Q2 2023.

Wilbanks Smith & Thomas Asset Management reported no remaining Alnylam Pharmaceuticals position as of Q2 2023 after selling out during the quarter.
Wilbanks Smith & Thomas Asset Management sold 1,000 Alnylam Pharmaceuticals shares in Q2 2023, an estimated $200K.
Wilbanks Smith & Thomas Asset Management first reported a position in Alnylam Pharmaceuticals in Q3 2022 and held it in 3 quarters.
Wilbanks Smith & Thomas Asset Management's Alnylam Pharmaceuticals position peaked at $238K in Q4 2022.
476 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2023.

Based on Wilbanks Smith & Thomas Asset Management's 13F filing for Q2 2023, filed 8 Aug 2023.